Preferred Label : CBL-B Inhibitor NX-1607;
NCIt synonyms : Casitas B-lineage Lymphoma B Inhibitor NX-1607; Casitas B-lineage Lymphoma Proto-oncogene-b Inhibitor NX-1607;
NCIt definition : An orally bioavailable, small-molecule inhibitor of Casitas B-lineage lymphoma proto-oncogene-b
(CBL-B), with potential immunomodulatory and antineoplastic activities. Upon oral
administration, CBL-B inhibitor NX-1607 targets, binds to and inhibits the activity
of CBL-B, which may result in immune activation, the infiltration of natural killer
(NK) cells and activated CD8 T-cells in the tumor microenvironment (TME), and the
inhibition of tumor growth. CBL-B, an E3 ubiquitin ligase expressed in all leukocyte
subsets including T-cells and NK cells, is a negative regulator of immune activation.;
Molecule name : NX 1607; NX-1607;
NCI Metathesaurus CUI : CL1773472;
Origin ID : C185125;
UMLS CUI : C5666942;
Semantic type(s)
- concept_is_in_subset
- has_target
